'I really think that TCAP scores don't really reflect people's intelligence': A Tennessee student with autism speaks out as lawmakers prepare to debate a bill that could shut down virtual schools ...

Abbott Laboratories' business, if not exciting, is resilient and consistent. The company is a leader in multiple markets and has attractive growth avenues. The medical device leader boasts a strong ...

Content scraping is harming the information business in ways that could not have been foreseen. Case in point: At least three major news organizations are blocking access to their content by the ...

A look at a massive tractor that’s built for serious work, towering over everything around it. It’s the kind of machine that makes you wonder who’s brave enough—and skilled enough—to take the wheel.

As Oregon’s energy demands increase, lawmakers are looking for ways to help cut the strain, at least during high peak times. A smart thermostat and electric vehicle. "Virtual power plants" can help ...

A Holland & Knight litigator is bringing what might be a precedent-setting suit against a medical researcher at MD Anderson Cancer Center in Houston that has long had sovereign immunity from ...

The tax-filing season is officially underway, and investors – especially those who are holding income-generating assets – will want to prepare to pay the tax man. The Internal Revenue Service began ...

OpenJDK project teams will focus work on features such as value types, code reflection, AOT compilation, and structured concurrency in the coming year. Oracle’s Java team in 2026 will work toward ...

SoFi Technology's appeal among younger customers could present an attractive long-term tailwind. Uber Technologies has yet to tap the full potential of its addressable market. Berkshire Hathaway ...

The announcement of Valve's upcoming Linux-based Steam Machine hit the internet with a largely positive reception — alongside some understandable confusion. Valve's console will purportedly offer up ...

Johnson & Johnson shares surged 46.3% in 2025 to all-time highs above $212 after bottoming near $141 in April. AbbVie yields 6.77% and has grown its dividend at a 10-12% annual rate over the past five ...